1. Home
  2. CTKB vs GBLI Comparison

CTKB vs GBLI Comparison

Compare CTKB & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • GBLI
  • Stock Information
  • Founded
  • CTKB 1990
  • GBLI 2016
  • Country
  • CTKB United States
  • GBLI United States
  • Employees
  • CTKB N/A
  • GBLI N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • GBLI Property-Casualty Insurers
  • Sector
  • CTKB Health Care
  • GBLI Finance
  • Exchange
  • CTKB Nasdaq
  • GBLI Nasdaq
  • Market Cap
  • CTKB 526.7M
  • GBLI 421.5M
  • IPO Year
  • CTKB 2021
  • GBLI 2003
  • Fundamental
  • Price
  • CTKB $4.02
  • GBLI $30.20
  • Analyst Decision
  • CTKB Hold
  • GBLI
  • Analyst Count
  • CTKB 4
  • GBLI 0
  • Target Price
  • CTKB $6.00
  • GBLI N/A
  • AVG Volume (30 Days)
  • CTKB 1.0M
  • GBLI 5.3K
  • Earning Date
  • CTKB 11-04-2025
  • GBLI 11-06-2025
  • Dividend Yield
  • CTKB N/A
  • GBLI 4.67%
  • EPS Growth
  • CTKB N/A
  • GBLI N/A
  • EPS
  • CTKB N/A
  • GBLI 1.98
  • Revenue
  • CTKB $196,035,000.00
  • GBLI $439,280,000.00
  • Revenue This Year
  • CTKB $0.09
  • GBLI $5.48
  • Revenue Next Year
  • CTKB $7.45
  • GBLI $7.91
  • P/E Ratio
  • CTKB N/A
  • GBLI $15.13
  • Revenue Growth
  • CTKB N/A
  • GBLI N/A
  • 52 Week Low
  • CTKB $2.37
  • GBLI $26.94
  • 52 Week High
  • CTKB $7.63
  • GBLI $37.00
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 53.78
  • GBLI 54.33
  • Support Level
  • CTKB $3.85
  • GBLI $29.55
  • Resistance Level
  • CTKB $4.23
  • GBLI $30.52
  • Average True Range (ATR)
  • CTKB 0.17
  • GBLI 0.51
  • MACD
  • CTKB -0.04
  • GBLI 0.18
  • Stochastic Oscillator
  • CTKB 40.70
  • GBLI 81.82

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About GBLI Global Indemnity Group LLC (DE)

Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.

Share on Social Networks: